Dr. Feldman on Durvalumab for Patients With Lung Cancer

Lawrence E. Feldman, MD
Published: Wednesday, Nov 08, 2017



Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.

This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.


Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab is a very exciting agent given the recently announced data that indicates an improvement in overall survival, especially in stage III patients with lung cancer.

This data shows that consolidation therapy after chemoradiation with durvalumab is a very promising combination. As a result, Feldman says he is looking forward to using durvalumab in his own practice.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x